Synergistic Enhancement of the Antitumor Effect of Taxol by the Bioreductive Compound NLCQ-1, In Vivo: Comparison with Tirapazamine

Oncology Research

Volumn 13, Issue 1, 2002, Pages 47-54

  Papadopoulou, Maria V ^a   Ji, Ming ^a   Bloomer, William D ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Hypoxic cytotoxins; NLCQ 1; Synergism; Taxol; Tirapazamine

Indexed keywords

CYTOTOXIN; PACLITAXEL; TIRAPAZAMINE; 4 (3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINO) 7 CHLOROQUINOLINE HYDROCHLORIDE; 4-(3-(2-NITRO-1-IMIDAZOLYL)-PROPYLAMINO)-7-CHLOROQUINOLINE HYDROCHLORIDE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR CELL; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; IMIDAZOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; PACLITAXEL; QUINOLINES; TRIAZINES;

EID: 0036368672     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504002108747953     Document Type: Article

References (43)

1. Hockel, M.; Schlenger, K.; Mitze, M.; Schaffer, U.; Vaupel, P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 6:3-9; 1996.
2. Siemann, D. W. Modification of chemotherapy by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys. 10:1585-1594; 1984.
3. Grau, C.; Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol. 13:301-309; 1988.
4. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res. 48:775-778; 1988.
5. Rice, G. C.; Hoy, C.; Schimke, R. T. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA 83: 5978-5982; 1986.
6. Teicher, B. A.; Holden, S. A.; al-Achi, A.; Herman, T. S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaII murine fibrosarcoma. Cancer Res. 50:3339-3344; 1990.
7. Siemann, D. W.; Mulcahy, R. T. Sensitization of cancer chemotherapeutic agents by nitroheterocyclics. Biochem. Pharmacol. 35: 111-115; 1986.
8. Holden, S. A.; Teicher, B. A.; Ara, G.; Herman, T. S.; Coleman, C. N. Enhancement of alkylating agent activity by SR-4233 in FSaIIC murine fibrosarcoma. J. Nat. Cancer Inst. 84:187-193; 1992.
9. Papadopoulou, M. V.; Mainwaring, A.; Bloomer, W. D. Potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea's toxicity in vitro by two new bioreductive agents. Jpn. J. Cancer Res. 83:907-913; 1992.
10. Dorie, M. J.; Brown, J. M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR4233) and cisplatin. Cancer Res. 53:4633-4636; 1993.
11. Papadopoulou, M. V.; Miller, A.; Seskey, T.; Epperly, M. W.; Bloomer, W. D. Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents. Radiat. Oncol. Invest. 1:206-217; 1993.
12. Langmuir, V. K.; Rooker, J. A.; Osen, M.; Mendonca, H. L.; Laderoute, K. R. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res. 54:2845-2847; 1994.
13. Siemann, D. W. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother. Oncol. 34:47-53; 1995.
14. Siemann, D. W. The in situ tumor response to combinations of cyclophosphamide and tirapazamine. Br. J. Cancer 74(Suppl. XX-VII):S65-S69; 1996.
15. Lartigau, E.; Guichard, M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumors. Br. J. Cancer 73:1480-1485; 1996.
16. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1 as radio/ chemosensitizer of EMT6 tumors in mice. Br. J. Cancer 74(Suppl. XXVII):S267-S270; 1996.
17. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1: A DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 10:49-58; 1996.
18. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol. Res. 9:249-257; 1997.
19. Dorie, M. J.; Brown, J. M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother. Pharmacol. 39:361-366; 1997.
20. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int. J. Radiat. Oncol. Biol. Phys. 42:775-779; 1998.
21. Kovacs, M. S.; Hocking, D. J.; Evans, J. W.; Siim, B. G.; Wouters, B. G. ; Brown, J. M. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer 80:1245-1251; 1999.
22. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother. Pharmacol. 48(2):160-168, 2001.
23. Friery, O. P.; Gallagher, R.; Murray, M. M.; Hughes, C. M.; Galligan, E. S.; McIntyre, I. A.; Patterson, L. H.; McKeown, S. R. Enhancement of the anti-tumor effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. Br. J. Cancer 82(8): 1469-1473; 2000.
24. Gallagher, R.; Hughes, C. M.; Murray, M. M.; Friery, O. P.; Patterson, L. H.; Hirst, D. G.; McKeown, S. R. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br. J. Cancer 85:625-629; 2001.
25. Miller, V. A.; Ng, K. K.; Grant, S. C.; Kindler, H.; Pizzo, B.; Heelan, R. T.; von Roemeling, R.; Kris, M. G. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 8:1269-1271; 1997.
26. Treat, J.; Johnson, E.; Langer, C.; Belani, C.; Haynes, B.; Greenberg, R.; Rodriquez, R.; Drobins, P.; Miller, W., Jr.; Meehan, L.; McKeon, A.; Devin, J.; von Roemeling, R.; Viallet, J. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study. J. Clin. Oncol. 16:3524-3527; 1998.
27. von Pawel, J.; von Roemeling, R.; Gatzemeier, U.; Boyer, M.; Elisson, L. O.; Clark, P.; Talbot, D.; Rey, A.; Butler, T. W.; Hirsh, V.; Olver, I.; Bergman, B.; Ayoub, J.; Richardson, G.; Dunlop, D.; Arcenas, A.; Vescio, R.; Viallet, J.; Treat, J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J. Clin. Oncol. 18:1351-1359; 2000.
28. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res. 12:185-192; 2000.
29. Hay, M. P.; Wilson, W. R.; Moselen, J. W.; Palmer, B. D.; Denny, W. A. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazoly-1)alkanecarboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J. Med. Chem. 37:381-391; 1994.
30. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol. Res. 12:325-333; 2000.
31. Blumenthal, R. D.; Taylor, A.; Osorio, L.; Ochakovskaya, R.; Raleigh, J. ; Papadopoulou, M.; Bloomer, W. D.; Goldenberg, D. M. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int. J. Cancer 94:564-571; 2001.
32. McGuire, W. P.; Rowinsky, E. K.; Rosenshine, N. B.; Grumbine, F. C.; Ettingger, D. S.; Armstrong, D. K.; Donehower, R. C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111: 273-279; 1989.
33. Etlinger, D. S. Overview of paclitaxel (taxol) in advanced lung cancer. Semin. Oncol. 20:46-49; 1993.
34. Forastiere, A. A. Use of paclitaxel (taxol) in squamous cell carcinoma of the head and neck. Semin. Oncol. 20:56-60, 1993.
35. Dorr, R. T.; Snead, K.; Liddil, J. D. Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 78:152; 1996.
36. Rockwell, S. C.; Kallman, R. F.; Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst. 49:735-749; 1972.
37. Hirst, D. G.; Brown, J. M.; Hazlehurst, J. L. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Cancer Res. 43:1961-1965; 1983.
38. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. Potentiation of chemotherapeutic drugs by the bioreductive compound NLCQ-1 against SCCVII tumors in mice. Proc. Am. Assoc. Cancer Res. Annu. Meet. 41:766-767; 2000.
39. Squillace, D. P.; Ruben, S. L.; Reid, J. M.; Ames, M. M. HPLC analysis and murine pharmacokinetics of the cytotoxic bioreductive agent NLCQ-1 (NSC 709257). Proc. Am. Assoc. Cancer Res. Annu. Meet. 41:706; 2000.
40. Aboagye, E. O.; Maxwell, R. J.; Kelson, A. B.; Tracy, M.; Lewis, A. D.; Graham, M. A.; Horsman, M. R.; Griffiths, J. R.; Workman, P. Preclinical evaluation of fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for measurement of tumor hypoxia. Cancer Res. 57:3314-3318, 1997.
41. Papadopoulou, M. V.; Ji, X.; Bloomer, W. D. Mechanisms involved in the potentiation of taxol or 5-FU by the hypoxic cytotoxin NLCQ-1. Clin. Cancer Res. 7(11)Suppl:3679s; 2001.
42. Milross, C. G.; Mason, K. A.; Hunter, N. R.; Chung, W. K.; Peters, L. J. ; Milas, L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst. 88:1308-1314; 1996.
43. Choy, H.; Rodriguez, F. F.; Koester, S.; Hilsenbeck, S.; Von Hoff, D. D. Investigation of taxol as a potential radiation sensitizer. Cancer 71: 3774-3778; 1993.